MedPath

Ascendis Pharma Bone Diseases A/S

🇩🇰Denmark
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:11
Completed:2

Trial Phases

2 Phases

Phase 1:11
Phase 3:1

Drug Approvals

1

EMA:1

Drug Approvals

Yorvipath

Authorization Status
Authorised
Approval Date
Nov 17, 2023
EMA

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Phase 1
11 (91.7%)
Phase 3
1 (8.3%)

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Conditions
Hypoparathyroidism
First Posted Date
2022-12-16
Last Posted Date
2025-06-27
Lead Sponsor
Ascendis Pharma Bone Diseases A/S
Registration Number
NCT05654701

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Phase 3
Completed
Conditions
Hypoparathyroidism
Endocrine System Diseases
Parathyroid Diseases
First Posted Date
2021-01-08
Last Posted Date
2025-03-18
Lead Sponsor
Ascendis Pharma Bone Diseases A/S
Target Recruit Count
84
Registration Number
NCT04701203
Locations
🇳🇴

Ascendis Pharma Investigational Site, Oslo, Norway

News

No news found
© Copyright 2025. All Rights Reserved by MedPath